vimarsana.com

Lobal Pharmaceutical Company And Sanotize Research Development Corp News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Glenmark Pharmaceuticals and SaNOtize Announce Peer Reviewed Publication of Its Phase 3 Clinical Trials on SaNOtize s Novel Nitric Oxide Nasal Spray for COVID-19 in Lancet Journal

MUMBAI, India and VANCOUVER, BC, July 13, 2022 /PRNewswire/ Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven, global pharmaceutical company and SaNOtize Research and Development Corp, today announced that The Lancet Regional Health Southeast Asia (TLRHSEA) - peer reviewed, high impact journal published the successful phase 3 clinical trial results of SaNOtize's Nitric Oxide Nasal Spray (NONS) study titled: 'SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trial'. https://www.thelancet.com/journals/lansea/article/PIIS2772-3682(22)00046-4/fulltext "We are excited to publish the study of the novel Nitric Oxide Nasal Spray, which positively impacts the lives of people, in The Lancet group of journals. The robust double-blind trial demonstrated significant efficacy and remarkable safety of NONS. This therapy has the potential to make a crucial contribution to COVID-19 management, with its ease of use in

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.